What is the appropriate acute and chronic management of hyperkalemia?

Management of Hyperkalemia

For acute hyperkalemia with ECG changes or K+ >6.5 mEq/L, immediately administer IV calcium (10 mL of 10% calcium gluconate) to stabilize cardiac membranes within 1-3 minutes, followed by insulin (10 units) with glucose (50 mL dextrose) and nebulized salbutamol (20 mg) to shift potassium intracellularly within 30-60 minutes, then initiate sodium zirconium cyclosilicate (SZC) 10g three times daily for total body potassium removal. 1

Acute Hyperkalemia Management

Immediate Stabilization (Life-Threatening)

The approach depends on severity and ECG manifestations rather than arbitrary thresholds 1:

First-line interventions (within minutes):

• IV calcium gluconate 10 mL of 10% - stabilizes cardiac membrane excitation in 1-3 minutes; does not lower potassium but prevents arrhythmias 1
• Monitor ECG continuously for peaked T-waves, widened QRS, or loss of P-waves

Second-line interventions (shift potassium intracellularly, 30-60 minutes):

• IV insulin 10 units + 50 mL dextrose - shifts K+ into cells but requires glucose to prevent hypoglycemia 1
• Nebulized salbutamol 20 mg in 4 mL - β2-agonist effect lasts only 2-4 hours; rebound hyperkalemia expected 1, 2
• IV sodium bicarbonate - only in patients with concurrent metabolic acidosis 1

Critical caveat: Insulin, salbutamol, and bicarbonate provide only temporary benefit (1-4 hours) and do not eliminate total body potassium. Rebound hyperkalemia occurs after 2 hours, necessitating early initiation of potassium-binding agents 2.

Total Body Potassium Removal

For acute settings with K+ ≥5.8 mEq/L:

• SZC 10g three times within 10 hours - reduces serum K+ by 0.72 mEq/L within 2 hours when added to standard therapy 1
• Onset of action: 1 hour (fastest available) 1

Alternative options:

• Loop diuretics - only in hypervolemic, non-oliguric patients with preserved kidney function 1
• Hemodialysis - for oliguria, ESRD, or resistant acute hyperkalemia 1

Chronic Hyperkalemia Management

Correction Phase (First 48 Hours)

SZC 10g three times daily for 48 hours is the preferred initial approach 1:

• Achieves mean K+ reduction of 1.1 mEq/L at 48 hours (P<0.001) 1
• Superior to all other doses tested in phase 3 trials 1

Patiromer alternative:

• Start 8.4g once daily, titrate up to 25.2g if needed 1
• Onset: 7 hours (slower than SZC) 1
• Must separate from other oral medications by ≥3 hours due to drug binding 1

Maintenance Phase (Long-Term)

After achieving normokalemia (K+ 3.5-5.0 mEq/L):

SZC maintenance dosing 1:

• Start 5-10g once daily
• Titrate in 5g increments (range: 5-15g daily) to maintain K+ 3.5-5.0 mEq/L
• 93% of patients maintained normokalemia over 11 months in HARMONIZE-OLE 1

Patiromer maintenance:

• Continue 8.4-25.2g once daily 1
• Maintained normokalemia for up to 12 months in patients with diabetes, CKD, and heart failure on RAASi therapy 1

Critical Management Principles

Do NOT discontinue RAASi therapy for hyperkalemia 1:

• Discontinuation increases mortality and major adverse cardiovascular events, particularly in patients with eGFR <30 mL/min/1.73m² 1
• Instead: treat hyperkalemia first, then reinitiate RAASi once K+ <5.0 mEq/L 1
• Newer potassium binders enable RAASi optimization and continuation 1

Monitoring strategy:

• Reassess K+ within 1 week after any RAASi initiation, dose change, or hyperkalemia episode 1
• Identify and remove other risk factors (NSAIDs, potassium supplements, trimethoprim) 1

Comparison of Potassium Binders

SZC advantages 1:

• Fastest onset (1 hour vs 7 hours for patiromer)
• Highly selective for K+ (also binds NH4+)
• No drug-drug interactions requiring separation
• Works in small and large intestines

SZC considerations 1:

• Contains 400mg sodium per 5g dose
• May cause dose-dependent edema
• Increases serum bicarbonate (beneficial in metabolic acidosis) 1

Patiromer advantages 1:

• No sodium content
• May benefit patients requiring sodium restriction
• Exchanges calcium for K+ (contains 1.6g calcium per 8.4g dose)

Patiromer considerations 1:

• Risk of hypercalcemia (underreported but documented)
• Risk of hypomagnesemia
• Requires 3-hour separation from other medications
• Slower onset (7 hours)

Avoid sodium polystyrene sulfonate (SPS) for chronic management 1:

• Contains 1500mg sodium per 15g dose
• Contains 20,000mg sorbitol per 15g dose (GI toxicity risk)
• Variable onset of action
• Nonselective binding
• Associated with serious adverse events

Common Pitfalls

1. Pseudohyperkalemia: Rule out hemolysis, repeated fist clenching, or poor phlebotomy technique before treating 1
2. Plasma vs serum: Plasma K+ is 0.1-0.4 mEq/L lower than serum due to platelet release during coagulation 1
3. Dietary restriction: Evidence for low-K+ diet effectiveness is limited; focus on reducing non-plant K+ sources rather than restricting all high-K+ foods 1
4. Rebound hyperkalemia: Expect after temporary measures (insulin, salbutamol); initiate binding agents early 2
5. RAASi discontinuation: Increases mortality risk; treat hyperkalemia instead of stopping life-saving medications 1